Financial Highlights
* Before
VetXX® rationalisation costs and amortisation of acquired intangibles.
Key Developments
- Robust organic growth in operating profit.
- VetXX acquisition fully integrated and performing in line with expectations.
- Product development progressing to schedule.
- Vetoryl® US FDA compliance notification received with US launch scheduled for January 2009.
- Key pharmaceuticals continue to increase market penetration.
- NVS® grew ahead of strong market growth.
- Dales continues to show good growth.